Exact Mass: 494.9950876

Exact Mass Matches: 494.9950876

Found 23 metabolites which its exact mass value is equals to given mass value 494.9950876, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dihydroneopterin triphosphate

{[({[(2R,3S)-3-(2-amino-4-oxo-1,4,7,8-tetrahydropteridin-6-yl)-2,3-dihydroxypropoxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}phosphonic acid

C9H16N5O13P3 (494.9957476)


The biosynthesis of tetrahydrobiopterin (BH4) from dihydroneopterin triphosphate (NH2P3) was studied in human liver extract. The phosphate-eliminating enzyme (PEE) was purified approximately 750-fold. The conversion of NH2P3 to BH4 was catalyzed by this enzyme in the presence of partially purified sepiapterin reductase, Mg2+, and NADPH. The PEE is heat stable when heated at 80°C for 5 min. It has a molecular weight of 63 000 daltons. One possible intermediate 6-(1-hydroxy-2-oxopropyl)5,6,7,8-tetrahydropterin(2-oxo-tetrahydropte rin) was formed upon incubation of BH4 in the presence of sepiapterin reductase and NADP+ at pH 9.0. The reduction of this compound with NaBD4 yielded monodeutero-, threo-, and erythro-BH4; the deuterium was incorporated at the 2 position. This and the UV spectra were consistent with a 2-oxo-tetrahydropterin structure. Dihydrofolate reductase (DHFR) catalyzed the reduction of BH2 into BH4 and was found to be specific for the pro-R-NADPH side. The sepiapterin reductase catalyzed the transfer of the pro-S hydrogen of NADPH during the reduction of sepiapterin into BH2. In the presence of crude liver extracts, the conversion of NH2P3 into BH4 requires NADPH. Two deuterium atoms were incorporated from (4S-2H)NADHP in the 1 and 2 position of the BH4 side chain. The incorporation of one hydrogen from the solvent was found at position C(6). These results are consistent with the occurrence of an intramolecular redox exchange between the pteridine nucleus and the side chain and formation of 6-pyruvoyl-5,6,7,8-tetrahydropterin(tetrahydro-1-2-dioxopterin) as an intermediate (PMID: 3930838). COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

7,8-Dihydromonapterin 3-triphosphate

7,8-Dihydromonapterin 3-triphosphate

C9H16N5O13P3 (494.9957476)


   

4-Chloro-N-[5-methyl-2-[7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl]-3-pyridyl]-3-(trifluoromethyl)benzenesulfonamide

4-chloro-N-(5-methyl-2-{7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl}pyridin-3-yl)-3-(trifluoromethyl)benzene-1-sulfonamide

C20H13ClF3N5O3S (495.03796940000007)


C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist

   
   

Dihydroneopterin triphosphate

7,8-Dihydroneopterin 3-triphosphate

C9H16N5O13P3 (494.9957476)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   
   

3,4-Dibromo-1-trityl-1H-pyrrole-2,5-dione

3,4-Dibromo-1-trityl-1H-pyrrole-2,5-dione

C23H15Br2NO2 (494.94694499999997)


   

2-Anthracenesulfonicacid, 1-amino-9,10-dihydro-4-[[(4-methylphenyl)sulfonyl]amino]-9,10-dioxo-,sodium salt (1:1)

2-Anthracenesulfonicacid, 1-amino-9,10-dihydro-4-[[(4-methylphenyl)sulfonyl]amino]-9,10-dioxo-,sodium salt (1:1)

C21H16N2NaO7S2+ (495.0296606)


   

SODIUM [(S)-1,2-DIAMINOPROPANE-N,N,N,N-TETRAACETATO]SAMARATE(III) HYDRATE

SODIUM [(S)-1,2-DIAMINOPROPANE-N,N,N,N-TETRAACETATO]SAMARATE(III) HYDRATE

C11H16N2NaO9Sm (494.9950876)


   

perfluoro-N-cyclohexylpyrrolidine

perfluoro-N-cyclohexylpyrrolidine

C10F19N (494.9727348)


   

Perfluoro-N-methyldecahydroisoquinoline

Perfluoro-N-methyldecahydroisoquinoline

C10F19N (494.9727348)


   

Perfluoro-4-methylquinolizidine

Perfluoro-4-methylquinolizidine

C10F19N (494.9727348)


   

N-[5-[[2-(4-acetamidoanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-5-bromo-2-furancarboxamide

N-[5-[[2-(4-acetamidoanilino)-2-oxoethyl]thio]-1,3,4-thiadiazol-2-yl]-5-bromo-2-furancarboxamide

C17H14BrN5O4S2 (494.96705440000005)


   

Dihydromonapterin triphosphate

Dihydromonapterin triphosphate

C9H16N5O13P3 (494.9957476)


   
   

Amino-hydroxy-hydroxypropyl-dihydropteridin

Amino-hydroxy-hydroxypropyl-dihydropteridin

C9H16N5O13P3-2 (494.9957476)


   

ethyl 4-cyano-5-[[2-[[5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]-3-methylthiophene-2-carboxylate

ethyl 4-cyano-5-[[2-[[5-(2,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]-3-methylthiophene-2-carboxylate

C19H15Cl2N5O3S2 (494.99933400000003)


   

N-(4-ethoxyphenyl)sulfonyl-N-(2-oxo-5-benzo[g][1,3]benzoxathiolyl)-2-furancarboxamide

N-(4-ethoxyphenyl)sulfonyl-N-(2-oxo-5-benzo[g][1,3]benzoxathiolyl)-2-furancarboxamide

C24H17NO7S2 (495.0446412)


   

UBP301 (hydrochloride)

UBP301 (hydrochloride)

C15H15ClIN3O6 (494.96941100000004)


UBP301 hydrochloride is a potent and selective antagonist of kainate receptor with IC50 and KD of 164 μM and 5.94 μM, respectively. UBP301 hydrochloride has ~30-fold selectivity of kainate receptor over AMPA receptor. UBP301 hydrochloride is the derivative of willardiine[1].

   

5,5,5-trichloro-2-(4,4-dichloro-n,3-dimethylbutanamido)-4-methyl-n-(1,3-thiazol-2-ylmethyl)pentanimidic acid

5,5,5-trichloro-2-(4,4-dichloro-n,3-dimethylbutanamido)-4-methyl-n-(1,3-thiazol-2-ylmethyl)pentanimidic acid

C16H22Cl5N3O2S (494.98753020000004)


   

(2r,4s)-5,5,5-trichloro-2-[(3s)-4,4-dichloro-n,3-dimethylbutanamido]-4-methyl-n-(1,3-thiazol-2-ylmethyl)pentanimidic acid

(2r,4s)-5,5,5-trichloro-2-[(3s)-4,4-dichloro-n,3-dimethylbutanamido]-4-methyl-n-(1,3-thiazol-2-ylmethyl)pentanimidic acid

C16H22Cl5N3O2S (494.98753020000004)


   

(2s,4s)-5,5,5-trichloro-2-[(3s)-4,4-dichloro-n,3-dimethylbutanamido]-4-methyl-n-(1,3-thiazol-2-ylmethyl)pentanimidic acid

(2s,4s)-5,5,5-trichloro-2-[(3s)-4,4-dichloro-n,3-dimethylbutanamido]-4-methyl-n-(1,3-thiazol-2-ylmethyl)pentanimidic acid

C16H22Cl5N3O2S (494.98753020000004)